Predictors of weight loss and maintenance in patients treated with antiobesity drugs

References

• James WP The epidemiology of obesity: the size of the problem J Intern Med 2008 263 4 336 352 18312311
   PubMed Web of Science ®Google Scholar
• Stein CJ Colditz GA The epidemic of obesity J Clin Endocrinol Metab 2004 89 6 2522 2525 15181019
   PubMed Web of Science ®Google Scholar
• Rankinen T Zuberi A Chagnon YC The human obesity gene map: the 2005 update Obesity (Silver Spring) 2006 14 4 529 644 16741264
   PubMed Web of Science ®Google Scholar
• World Health Organization Obesity: preventing and managing the global epidemic Geneva, Switzerland Report of a WHO consultation. Technical Report Series 894. 2000
   Google Scholar
• Tsigos C Hainer V Basdevant A Management of obesity in adults: European clinical practice guidelines Obes Facts 2008 1 2 106 116 20054170
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration News Release. FDA expands use of banding system for weight loss. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm. Accessed 23 May, 2011.
   Google Scholar
• Halpern A Mancini MC Treatment of obesity: an update on anti-obesity medications Obes Rev 2003 4 1 25 42 12608525
   PubMedGoogle Scholar
• Ioannides-Demos LL Proietto J McNeil JJ Pharmacotherapy for obesity Drugs 2005 65 10 1391 1418 15977970
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Dubnov-Raz G Berry EM The dietary treatment of obesity Endocrinol Metab Clin North Am 2008 37 4 873 886 19026937
   PubMed Web of Science ®Google Scholar
• Clifton PM Dietary treatment for obesity Nat Clin Pract Gastroenterol Hepatol 2008 5 12 672 681 18852729
   PubMedGoogle Scholar
• Sodlerlund A Fischer A Johansson T Physical activity, diet and behaviour modification in the treatment of overweight and obese adults: a systematic review Perspect Public Health 2009 129 3 132 142 19514637
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674 21197148
   PubMedGoogle Scholar
• Leff DR Heath D Surgery for obesity in adulthood BMJ 2009 339 b3402 19773325
   PubMed Web of Science ®Google Scholar
• Baker MK Byrne TK Feldmann ME Surgical treatment of obesity Prim Care 2009 36 2 417 427 19501252
   PubMed Web of Science ®Google Scholar
• Seaton DA Rose K Defaulters from a weight reduction clinic J Chronic Dis 1965 18 10 1007 1011 5835009
   PubMedGoogle Scholar
• Silverstone JT Solomon T Psychiatric and somatic factors in the treatment of obesity J Psychosom Res 1965 9 3 249 255 5849892
   PubMed Web of Science ®Google Scholar
• Teixeira PJ Going SB Sardinha LB Lohman TG A review of psychosocial pre-treatment predictors of weight control Obes Rev 2005 6 1 43 65 15655038
   PubMed Web of Science ®Google Scholar
• Elfhag K Rossner S Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain Obes Rev 2005 6 1 67 85 15655039
   PubMed Web of Science ®Google Scholar
• Moreno-Aliaga MJ Santos JL Marti A Martinez JA Does weight loss prognosis depend on genetic make-up? Obes Rev 2005 6 2 155 168 15836466
   PubMed Web of Science ®Google Scholar
• Herpertz S Kielmann R Wolf AM Hebebrand J Senf W Do psychosocial variables predict weight loss or mental health after obesity surgery? A systematic review Obes Res 2004 12 10 1554 1569 15536219
   PubMedGoogle Scholar
• Kral JG Selection of patients for anti-obesity surgery Int J Obes Relat Metab Disord 2001 25 Suppl 1 S107 S112 11466602
   PubMed Web of Science ®Google Scholar
• Brownell KD Behavioral, psychological, and environmental predictors of obesity and success at weight reduction Int J Obes 1984 8 5 543 550 6394524
   PubMed Web of Science ®Google Scholar
• Hainer V Kunesova M Bellisle F Hill M Braunerova R Wagenknecht M Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine Int J Obes (Lond) 2005 29 2 208 216 15583700
   PubMed Web of Science ®Google Scholar
• Peters WR MacMurry JP Walker J Giese RJJr Comings DE Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women Obes Res 2003 11 3 415 419 12634439
   PubMedGoogle Scholar
• Rissanen A Lean M Rossner S Segal KR Sjostrom L Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines Int J Obes Relat Metab Disord 2003 27 1 103 109 12532161
   PubMed Web of Science ®Google Scholar
• Elfhag K Rossner S Carlsson AM Barkeling B Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data Obes Res 2003 11 11 1391 1399 14627761
   PubMedGoogle Scholar
• Elfhag K Rossner S Barkeling B Rooth P Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood Pharmacol Res 2005 51 2 159 163 15629262
   PubMed Web of Science ®Google Scholar
• Finer N Ryan DH Renz CL Hewkin AC Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients Diabetes Obes Metab 2006 8 2 206 213 16448525
   PubMed Web of Science ®Google Scholar
• Norris SL Zhang X Avenell A Gregg E Schmid CH Lau J Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus Cochrane Database Syst Rev. 2005 1 CD004096 15674929
   PubMed Web of Science ®Google Scholar
• Ullrich A Erdmann J Margraf J Schusdziarra V Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat Aliment Pharmacol Ther 2003 17 8 1007 1013 12694082
   PubMed Web of Science ®Google Scholar
• Guerciolini R Mode of action of orlistat Int J Obes Relat Metab Disord 1997 21 Suppl 3 S12 S23 9225172
   PubMed Web of Science ®Google Scholar
• Rucker D Padwal R Li SK Curioni C Lau DC Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 2007 335 7631 1194 1199 18006966
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [FDA] Early communication about an ongoing safety review orlistat (marketed as Alli and Xenical) FDA Silver Spring, MD 2011
   Google Scholar
• Elfhag K Finer N Rossner S Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success Diabetes Obes Metab 2008 10 6 498 505 17593239
   PubMed Web of Science ®Google Scholar
• European Agency for Evaluation of Medical Products Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR): Xenical. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000154/WC500058428.pdf. 2011.
   Google Scholar
• Lloret-Linares C Greenfield JR Czernichow S Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review Diabet Med 2008 25 10 1142 1450 19046191
   PubMed Web of Science ®Google Scholar
• Toplak H Ziegler O Keller U X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance Diabetes Obes Metab 2005 7 6 699 708 16219013
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE) guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children Available at: http://www.nice.org.uk/nicemedia/live/11000/30365/30365.pdf. 2006.
   Google Scholar
• Malone M Alger-Mayer SA Pharmacist intervention enhances adherence to orlistat therapy Ann Pharmacother 2003 37 11 1598 1602 14565841
   PubMed Web of Science ®Google Scholar
• Rodin J Bray GA Atkinson RL Predictors of successful weight loss in an outpatient obesity clinic Int J Obes 1977 1 1 79 87 617110
   PubMed Web of Science ®Google Scholar
• Lean ME How does sibutramine work? Int J Obes Relat Metab Disord 2001 25 Suppl 4 S8 S11 11916106
   PubMed Web of Science ®Google Scholar
• Hansen DL Toubro S Stock MJ Macdonald IA Astrup A The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction Int J Obes Relat Metab Disord 1999 23 10 1016 1024 10557021
   PubMed Web of Science ®Google Scholar
• Vazquez Roque MI Camilleri M Clark MM Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine Clin Gastroenterol Hepatol 2007 5 7 829 837 17544870
   PubMed Web of Science ®Google Scholar
• Fabricatore AN Wadden TA Moore RH Butryn ML Heymsfield SB Nguyen AM Predictors of attrition and weight loss success: results from a randomized controlled trial Behav Res Ther 2009 47 8 685 691 19497559
   PubMed Web of Science ®Google Scholar
• Hansen D Astrup A Toubro S Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance Int J Obes Relat Metab Disord 2001 25 4 496 501 11319653
   PubMed Web of Science ®Google Scholar
• Grudell AB Sweetser S Camilleri M A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults Gastroenterology 2008 135 4 1142 1154 18725220
   PubMed Web of Science ®Google Scholar
• van Baak MA van ME Astrup AV Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial) Am J Clin Nutr 2003 78 2 209 214 12885699
   PubMed Web of Science ®Google Scholar
• US and European prescribing information. Abbott Laboratories. 2010.
   Google Scholar
• Frey UH Hauner H Jockel KH Manthey I Brockmeyer N Siffert W A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation Pharmacogenet Genomics 2008 18 2 141 151 18192900
   PubMed Web of Science ®Google Scholar
• Danoviz ME Pereira AC Mill JG Krieger JE Hypertension, obesity and GNB 3 gene variants Clin Exp Pharmacol Physiol 2006 33 3 248 252 16487269
   PubMed Web of Science ®Google Scholar
• Ryden M Faulds G Hoffstedt J Wennlund A Arner P Effect of the (C825T) Gbeta(3) polymorphism on adrenoceptor-mediated lipolysis in human fat cells Diabetes 2002 51 5 1601 1608 11978662
   PubMed Web of Science ®Google Scholar
• Hauner H Meier M Jockel KH Frey UH Siffert W Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism Pharmacogenetics 2003 13 8 453 459 12893983
   PubMedGoogle Scholar
• Hsiao DJ Wu LS Huang SY Lin E Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene Pharmacogenet Genomics 2009 19 9 730 733 19687782
   PubMed Web of Science ®Google Scholar
• Wong DL Lesage A Siddall B Funder JW Glucocorticoid regulation of phenylethanolamine N-methyltransferase in vivo FASEB J 1992 6 14 3310 3315 1426768
   PubMed Web of Science ®Google Scholar
• Heils A Teufel A Petri S Allelic variation of human serotonin transporter gene expression J Neurochem 1996 66 6 2621 2624 8632190
   PubMed Web of Science ®Google Scholar
• Hsiao TJ Wu LS Hwang Y Huang SY Lin E Effect of the common −866G/A polymorphism of the uncopling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population Mol Diagn Ther 2010 14 2 101 106 20359253
   PubMed Web of Science ®Google Scholar
• Dalgaard LT Pedersen O Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and type II diabetes Diabetologia 2001 44 8 946 965 11484071
   PubMed Web of Science ®Google Scholar
• Tankova T Dakovska G Lazarova M Dakovska L Kirilov G Koev D Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects Acta Diabetol 2004 41 4 146 153 15660196
   PubMed Web of Science ®Google Scholar
• Reductil (sibutramine hydrochloride) Australian prescribing information. Abbott Australasia Pty Ltd. March 5, 2004.
   Google Scholar
• James WP Astrup A Finer N Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet 2000 356 9248 2119 2125 11191537
   PubMed Web of Science ®Google Scholar
• Sjostrom L Rissanen A Andersen T Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 1998 352 9123 167 172 9683204
   PubMed Web of Science ®Google Scholar
• Risser JA Vash PD Nieto L Does prior authorization of sibutramine improve medication compliance or weight loss? Obes Res 2005 13 1 86 92 15761166
   PubMedGoogle Scholar
• Inoue S Clinical studies with mazindol Obes Res. 1995 3 Suppl 4 549S 552S 8697057
   PubMedGoogle Scholar
• Womble LG Williamson DA Greenway FL Redmann SM Psychological and behavioral predictors of weight loss during drug treatment for obesity Int J Obes Relat Metab Disord 2001 25 3 340 345 11319630
   PubMed Web of Science ®Google Scholar
• Shimizu H Mori M Trp64Arg mutation of beta-2 adrenergic receptor gene determines weight losing effect of mazindol Obes Res 2004 12 Suppl A37
   Google Scholar
• Shimizu H Tsuchiya T Oh-I S Ohtani K-I Okada S Mori M Incidence of beta3-adrenergic receptor polymorphism and prediction of successful weight reduction with mazindol therapy in severely obese Japanese subjects Obes Res Clin Pract 2007 1 119 123
   Web of Science ®Google Scholar
• Schiffelers SL Saris WH Boomsma F van Baak MA beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men J Clin Endocrinol Metab 2001 86 5 2191 2199 11344226
   PubMed Web of Science ®Google Scholar
• Yamamura S Hamaguchi T Ohoyama K Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin Epilepsy Res 2009 84 172 186 19268540
   PubMed Web of Science ®Google Scholar
• Richard D Ferland J Lalonde J Samson P Deshaies Y Influence of topiramate in the regulation of energy balance Nutrition 2000 16 961 966 11054602
   PubMed Web of Science ®Google Scholar
• Liang Y She P Wang X Demarest K The messenger RNA profiles in liver, hypothalamus, white adipose tissue and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment Metabolism 2006 55 1411 1419 16979414
   PubMed Web of Science ®Google Scholar
• De Simone G Di Fiore A Supuran CT Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008 14 655 660 18336311
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hollander P Gadde K Sun X Strauss R Leung A A randomised, doubleblind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients Diab Care 2007 30 1480 1486
   PubMed Web of Science ®Google Scholar
• Theisen FM Beyenburg S Gebhardt S A prospective study of body weight and serum leptin levels in patients treated with topiramate Clin Neuropharmacol 2008 31 4 226 230 18670246
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E Axelsen M Johanson EH Stagge A Smith U Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 2003 11 4 556 562 12690085
   PubMedGoogle Scholar
• Klein KM Theisen F Knake S Topiramate, nutrition and weight change: a prospective study J Neurol Neurosurg Psychiatry 2008 79 590 593
   Google Scholar
• Alberici A Borroni B Manelli F Topiramate weight loss in migraine patients J Neurol Sci 2009 278 1–2 64 65 19084843
   PubMed Web of Science ®Google Scholar
• Greenway F Obesity medications and the treatment of type 2 diabetes Diabetes Technol Ther 1999 1 3 277 287 11475274
   PubMedGoogle Scholar
• Greenway FL Fujioka K Plodkowski RA COR-I Study Group Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 Erratum in: Lancet. 2010;376(9741):594. Lancet. 2010;376(9750):1392. 20673995
   PubMed Web of Science ®Google Scholar